4 treatment settings, 3 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
H1 and H2 antihistamines, cromolyn, leukotriene antagonists, omalizumab for anaphylaxis, epinephrine autoinjector, bone protection; avapritinib 25 mg daily to start for moderate to severe symptoms uncontrolled by these (PIONEER); the US label advises against it when platelets are below 50 x 10^9/L.
Avapritinib is the first drug for GIST driven by the PDGFRA D842V mutation, which resists every other kinase inhibitor; it is also approved for systemic mastocytosis.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Cognitive effects · NAVIGATOR, 300 or 400 mg daily, N=204 | 48% | 4.9% |
| Oedema, including periorbital and facial · NAVIGATOR, 300 or 400 mg daily, N=204 | 72% | 2% |
| Intracranial haemorrhage · Patients with GIST in the label, 3 of 267 | 1.1% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.
Avapritinib 200 mg daily (platelets above 50 x 10^9/L) as preferred agent; midostaurin as alternative or where platelets are low.
Avapritinib is the first drug for GIST driven by the PDGFRA D842V mutation, which resists every other kinase inhibitor; it is also approved for systemic mastocytosis.
The first drug to improve survival in FLT3-mutated AML, added to standard chemotherapy: the risk of death fell by 22%. Median survival was 74.7 against 25.6 months, though the trial's authors call the 22% figure the more accurate measure.
Pills that block the specific enzyme a cancer relies on. Imatinib in 2001 proved a cancer could be switched off by design.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Cognitive effects · NAVIGATOR, 300 or 400 mg daily, N=204 | 48% | 4.9% |
| Oedema, including periorbital and facial · NAVIGATOR, 300 or 400 mg daily, N=204 | 72% | 2% |
| Intracranial haemorrhage · Patients with GIST in the label, 3 of 267 | 1.1% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Febrile neutropenia · RATIFY midostaurin arm with chemotherapy (83% with placebo); not drug-specific | - | 84% |
| QT prolongation · RATIFY midostaurin arm with chemotherapy (17% and 5% with placebo); monitor, avoid strong CYP3A4 inhibitors where possible | 20% | 6% |
| Nausea · RATIFY midostaurin arm with chemotherapy (70% with placebo) | 83% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.
Switch between avapritinib and midostaurin; cladribine; clinical trials (bezuclastinib, elenestinib); allogeneic transplant for mast cell leukaemia or high-risk SM-AHN.
A one-week infusion that puts most people with hairy cell leukaemia into remission for years; also used in multiple sclerosis in tablet form.
Allogeneic stem cell transplantation replaces a patient's blood system with a donor's after conditioning chemotherapy, so donor immune cells hunt down leukaemia left behind. It remains the only cure for adverse-risk acute myeloid leukaemia, high-risk acute lymphoblastic leukaemia and Richter transformation, at the price of graft-versus-host disease.
The first drug to improve survival in FLT3-mutated AML, added to standard chemotherapy: the risk of death fell by 22%. Median survival was 74.7 against 25.6 months, though the trial's authors call the 22% figure the more accurate measure.
Avapritinib is the first drug for GIST driven by the PDGFRA D842V mutation, which resists every other kinase inhibitor; it is also approved for systemic mastocytosis.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Febrile neutropenia · RATIFY midostaurin arm with chemotherapy (83% with placebo); not drug-specific | - | 84% |
| QT prolongation · RATIFY midostaurin arm with chemotherapy (17% and 5% with placebo); monitor, avoid strong CYP3A4 inhibitors where possible | 20% | 6% |
| Nausea · RATIFY midostaurin arm with chemotherapy (70% with placebo) | 83% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Cognitive effects · NAVIGATOR, 300 or 400 mg daily, N=204 | 48% | 4.9% |
| Oedema, including periorbital and facial · NAVIGATOR, 300 or 400 mg daily, N=204 | 72% | 2% |
| Intracranial haemorrhage · Patients with GIST in the label, 3 of 267 | 1.1% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.
Treat the dominant component: KIT inhibitor for mast cell burden plus the standard therapy for the associated CMML, MDS or AML (hypomethylating agents, intensive chemotherapy, transplant).
A gentle chemotherapy that switches silenced genes back on. With venetoclax it became the standard for older people with AML who cannot take intensive treatment.
Allogeneic stem cell transplantation replaces a patient's blood system with a donor's after conditioning chemotherapy, so donor immune cells hunt down leukaemia left behind. It remains the only cure for adverse-risk acute myeloid leukaemia, high-risk acute lymphoblastic leukaemia and Richter transformation, at the price of graft-versus-host disease.
Avapritinib is the first drug for GIST driven by the PDGFRA D842V mutation, which resists every other kinase inhibitor; it is also approved for systemic mastocytosis.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia · VIALE-A, azacitidine with venetoclax (28% with azacitidine and placebo) | - | 42% |
| Febrile neutropenia · VIALE-A, azacitidine with venetoclax (19% with azacitidine and placebo) | - | 42% |
| Nausea · VIALE-A, azacitidine with venetoclax (35% with azacitidine and placebo) | 44% | - |
| Injection-site reactions · Subcutaneous azacitidine alone in myelodysplastic syndromes (US label Study 4, N=175); injection-site erythema 43% | 29% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Cognitive effects · NAVIGATOR, 300 or 400 mg daily, N=204 | 48% | 4.9% |
| Oedema, including periorbital and facial · NAVIGATOR, 300 or 400 mg daily, N=204 | 72% | 2% |
| Intracranial haemorrhage · Patients with GIST in the label, 3 of 267 | 1.1% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.